This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
healthcare: Archive
The Longevity Shift: Healthcare REITs to Benefit From Global Aging
by Urmimala Biswas
WELL, VTR, CTRE and OHI are tapping the longevity economy as aging populations drive rising demand for senior housing, skilled nursing and long-term care real estate.
VTRPositive Net Change OHINegative Net Change CTREPositive Net Change WELLPositive Net Change
finance healthcare medical medical-devices
Tempus AI Revenue Jumps 85% as Pricing Catalysts Line Up
by Urmimala Biswas
Tempus AI's Q3 revenue surged as oncology and hereditary testing led the way, margins improved, and pricing tailwinds and regulatory milestones took shape.
TXGPositive Net Change DOCSPositive Net Change TEMPositive Net Change
artificial-intelligence earnings-growth earnings-outlook healthcare medical medical-devices
Tempus AI Near $75 Target? Valuation, Upside and Risks
by Urmimala Biswas
Tempus AI's rally meets a $75 target. Here's how valuation, catalysts, risks, and key numbers set up the risk-reward into 2026.
TXGPositive Net Change DOCSPositive Net Change TEMPositive Net Change
artificial-intelligence healthcare medical medical-devices
Is Tempus AI Stock a Buy Now or a Hold After a Big 2025 Run?
by Urmimala Biswas
Tempus AI rallies in 2025, but a Hold rank and mixed style scores argue for patience until pricing, FDA, and MRD milestones firm up.
IQVPositive Net Change GHPositive Net Change TEMPositive Net Change
artificial-intelligence earnings-report healthcare medical medical-devices valuation
Tempus AI: Data Flywheel and MRD Expansion Reshape the Outlook
by Urmimala Biswas
Tempus AI's data engine, MRD buildout and ADLT milestones set the stage for faster growth while profitability metrics turn the corner.
ILMNPositive Net Change GHPositive Net Change TEMPositive Net Change
artificial-intelligence earnings-report healthcare medical medical-devices
Tempus AI: Revenue Mix and 2026 Growth Outlook Explained
by Urmimala Biswas
Tempus AI's balanced genomics and data engine is scaling fast as profitability metrics improve and 2026 revenue targets approach the billion-plus mark.
EXASNo Net Change GHPositive Net Change TEMPositive Net Change
healthcare medical medical-devices oncology-screening
Is UnitedHealth's Valuation Dip & Divestment Diet a Real Buy Window?
by Kaibalya Pravo Dey
UNH trades below its five-year median P/E as it navigates margin pressure, membership declines and strategic divestments.
UNHNegative Net Change HUMNegative Net Change ELVPositive Net Change
healthcare hmo insurance insurance-premium medical
Battle of Benefits: Will UNH Deliver the Bigger Dose or CVS? (Revised)
by Rajshree Sipani
CVS's rising margins, stronger guidance and sharper valuation edge make it stand out in the UNH vs. CVS upside debate.
UNHNegative Net Change CVSPositive Net Change
healthcare hmo insurance medical smart-health
Battle of Benefits: Will UNH Deliver the Bigger Dose or CVH?
by Rajshree Sipani
CVS's rising margins, stronger guidance and sharper valuation edge make it stand out in the UNH vs. CVS upside debate.
UNHNegative Net Change CVSPositive Net Change
healthcare hmo insurance medical smart-health
Demographic Megatrend: Stocks Poised to Benefit From Global Aging
by Urmimala Biswas
Global aging is reshaping healthcare demand. Discover how AbbVie, Amgen, Boston Scientific and Edwards are positioned to gain from this powerful megatrend.
BSXPositive Net Change AMGNPositive Net Change EWPositive Net Change OHINegative Net Change ABBVPositive Net Change CTREPositive Net Change ENSGNegative Net Change
biotechs cell-therapy gene-therapy genetics genomics healthcare hospitals medical medical-devices
UnitedHealth Recovers Its Rhythm Before Q3 Earnings: Time to Buy?
by Kaibalya Pravo Dey
UNH's Q3 results hinge on premium growth and Optum gains amid rising costs and margin pressure.
UNHNegative Net Change HUMNegative Net Change MOHNegative Net Change
earnings-outlook earnings-preview healthcare hmo insurance insurance-premium medical
UNH vs. HUM: Which Healthcare Stock is the Healthier Buy Now?
by Kaibalya Pravo Dey
Humana's sharper Medicare focus, cost discipline and leaner structure position it ahead of UnitedHealth in the healthcare stock race.
UNHNegative Net Change HUMNegative Net Change
healthcare hmo insurance medical
Abbott Q3 Earnings Review: Tariff, Diagnostics Cap Near-Term Gains
by Urmimala Biswas
Abbott posts strong Q3 growth across key segments, but tariff pressures and weak Diagnostics weigh on near-term momentum.
ABTNegative Net Change BSXPositive Net Change MDTNegative Net Change
earnings-estimates-revisions earnings-outlook earnings-preview earnings-report earnings-streak earnings-surprise healthcare medical medical-devices
UnitedHealth Jumps 12% in a Month: But is it Healthy Enough to Buy?
by Kaibalya Pravo Dey
UNH surges 12% in a month, but with rising costs and regulatory pressures, is now the time to buy or wait?
UNHNegative Net Change BRK.BPositive Net Change HUMNegative Net Change ELVPositive Net Change
healthcare hmo insurance medical
UnitedHealth vs. Molina: Who's Poised for the Healthiest Comeback?
by Kaibalya Pravo Dey
Health insurers are facing turbulence, but which stock is set to rebound stronger: the diversified giant UNH or Medicaid-focused MOH?
UNHNegative Net Change BRK.BPositive Net Change MOHNegative Net Change
healthcare hmo insurance medical
UnitedHealth Reaffirms 2025 EPS Guidance: Time to Buy or Wait?
by Kaibalya Pravo Dey
UNH reaffirms its 2025 EPS outlook, but mounting costs, legal probes and valuation pressures cloud the path ahead.
UNHNegative Net Change BRK.BPositive Net Change MOHNegative Net Change CNCPositive Net Change
earnings-outlook healthcare hmo insurance medical
Investing in the Age of Longevity: Silver Economy Stocks in Focus
by Urmimala Biswas
AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.
ABTNegative Net Change AMGNPositive Net Change MDTNegative Net Change SYKPositive Net Change DXCMPositive Net Change ABBVPositive Net Change
biotechnology biotechs healthcare medical medical-devices robotics
Tempus AI or Butterfly: Which AI Health Tech Stock is a Buy Now?
by Urmimala Biswas
BFLY trades at distressed levels with analyst targets signaling sharp upside, while TEM's premium valuation tempers its appeal.
AZNPositive Net Change NVDAPositive Net Change BFLYPositive Net Change TEMPositive Net Change
artificial-intelligence earnings-outlook earnings-report earnings-surprise healthcare medical medical-devices smart-health
Tempus AI Stock Jumps Post Q2 as EBITDA Breakeven Nears: Buy or Hold?
by Urmimala Biswas
Tempus AI's soaring Q2 revenues, margin gains and near-EBITDA breakeven position it as a fast-rising force in precision medicine.
IRTCPositive Net Change SOPHPositive Net Change TEMPositive Net Change
artificial-intelligence earnings-outlook earnings-report earnings-surprise healthcare medical medical-devices
When a Healthcare Giant Gets Sick: Elevance Health's 20% YTD Decline
by Kaibalya Pravo Dey
ELV's 20% YTD slump reflects shrinking memberships, rising costs and deepening analyst pessimism despite long-term growth levers.
UNHNegative Net Change CNCPositive Net Change ELVPositive Net Change
earnings-outlook healthcare hmo insurance insurance-premium medical
Is CVS a Smart Buy Now on Strong Q2, Low Valuation & Long-Term Upside?
by Urmimala Biswas
CVS appears well-poised on strong Q2 revenue growth, raised full-year guidance and momentum in key healthcare segments.
UNHNegative Net Change CVSPositive Net Change HLFNegative Net Change
earnings-estimates-revisions earnings-outlook earnings-preview earnings-report earnings-surprise healthcare medical medical-devices
UnitedHealth Crashing After Q2 Shock: Should You Panic or Pounce?
by Kaibalya Pravo Dey
UNH plunges 12.9% after weak Q2 and slashing 2025 EPS guidance, sparking fears of deeper structural issues ahead.
UNHNegative Net Change MOHNegative Net Change CNCPositive Net Change
earnings-outlook earnings-surprise healthcare hmo insurance medical
Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy?
by Urmimala Biswas
TEM surged 34.5% in Q2 on AI-driven deals and product momentum, but valuation and profit concerns linger ahead of earnings.
AZNPositive Net Change TXGPositive Net Change SOPHPositive Net Change TEMPositive Net Change
artificial-intelligence earnings-estimates-revisions earnings-outlook earnings-preview earnings-report earnings-streak earnings-surprise healthcare medical medical-devices smart-health
Tempus AI or NVIDIA: Which is the Smarter Bet in AI-Backed Healthcare?
by Urmimala Biswas
Tempus AI surges 91.8% YTD with soaring genomics revenues and a $200M AstraZeneca deal, outpacing NVIDIA in AI healthcare gains.
AZNPositive Net Change NVOPositive Net Change NVDAPositive Net Change TEMPositive Net Change
artificial-intelligence healthcare medical medical-devices smart-health tech-stocks
CVS or UnitedHealth: Which Stock Is a Better Buy Ahead of Q2 Earnings?
by Urmimala Biswas
CVS shows resilience with stable insurance margins and capital discipline, while UNH faces cost headwinds and a sharp earnings cut.
UNHNegative Net Change CVSPositive Net Change
earnings-estimates-revisions earnings-outlook earnings-preview earnings-report healthcare medical medical-devices retail